Abstract
Background
The totally subcutaneous implantable defibrillator (S-ICD) was introduced as a new alternative to conventional implantable defibrillators and is employed worldwide. This system is especially attractive for young patients. However, in patients with hypertrophic cardiomyopathy (HCM), T-wave oversensing may occur. To address the question whether the S-ICD system is suitable for HCM patients, the data of a standard of care prospective single-center S-ICD registry were evaluated.
Methods and results
In the present study, 18 HCM patients who received an S-ICD for primary (n = 14) or secondary prevention (n = 4) and a minimal follow-up duration of 6 months were analyzed. The mean follow-up duration was 31.7 ± 15.4 months. Ventricular arrhythmias were adequately detected in 4 patients (22 %). In 7 patients (39 %), T-wave oversensing was noticed and led to at least one inappropriate shock in 4 patients (22 %). Further adverse events included surgical revision due to a mobile sensing electrode and resulting noise detection as well as one case of early battery failure requiring pulse generator change.
Conclusion
Patients with HCM and S-ICD systems have an increased risk of T-wave oversensing and inappropriate shock delivery. Thorough monitoring as well as exercise tests may help to improve device settings and thereby prevent T-wave oversensing.
Similar content being viewed by others
References
Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Avid, cash and cids studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study hamburg. Canadian implantable defibrillator study. Eur Heart J 21:2071–2078
Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS (2004) Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44:2166–2172
Backhoff D, Muller M, Ruschewski W, Paul T, Krause U (2014) Icd therapy for primary prevention of sudden cardiac death after mustard repair for d-transposition of the great arteries. Clin Res Cardiol 103:894–901
Kolb C, Lennerz C, Semmler V, Jilek C (2013) Primary prevention of sudden cardiac death with an entirely subcutaneous defibrillator in a patient with a large right atrial thrombus. Clin Res Cardiol 102:169–170
Alcalde M, Campuzano O, Sarquella-Brugada G, Arbelo E, Allegue C, Partemi S, Iglesias A, Oliva A, Brugada J, Brugada R (2015) Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy. Clin Res Cardiol 104:288–303
Bobinger T, Kallmunzer B, Kopp M, Kurka N, Arnold M, Hilz MJ, Huttner HB, Schwab S, Kohrmann M (2015) Prevalence and impact on outcome of electrocardiographic early repolarization patterns among stroke patients: a prospective observational study. Clin Res Cardiol 104:666–671
Yamazawa H, Takeda A, Takei K, Furukawa T (2014) Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging. Clin Res Cardiol 103:75–77
Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB, Hood M, Pedersen S, Kaab S, Murgatroyd F, Reeve HL, Carter N, Boersma L (2014) Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the effortless s-icd registry. Eur Heart J 35:1657–1665
Burke MC, Gold MR, Knight BP, Barr CS, Theuns DA, Boersma LV, Knops RE, Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD (2015) Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the ide study and effortless registry. J Am Coll Cardiol 65:1605–1615
Aziz S, Leon AR, El-Chami MF (2014) The subcutaneous defibrillator: a review of the literature. J Am Coll Cardiol 63:1473–1479
Dabiri Abkenari L, Theuns DA, Valk SD, Van Belle Y, de Groot NM, Haitsma D, Muskens-Heemskerk A, Szili-Torok T, Jordaens L (2011) Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 100:737–744
Olde Nordkamp LR, Abkenari LD, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE (2012) The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large dutch cohort. J Am Coll Cardiol 60:1933–1939
Jarman JW, Todd DM (2013) United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace 15:1158–1165
Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, Rashtian M, Kremers M, Crozier I, Lee KL, Smith W, Burke MC (2013) Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 128:944–953
Guenther M, Kolschmann S, Knaut M (2015) Substernal lead implantation: a novel option to manage dft failure in s-icd patients. Clin Res Cardiol 104:189–191
Olde Nordkamp LR, Brouwer TF, Barr C, Theuns DA, Boersma LV, Johansen JB, Neuzil P, Wilde AA, Carter N, Husby M, Lambiase PD, Knops RE (2015) Inappropriate shocks in the subcutaneous icd: incidence, predictors and management. Int J Cardiol 195:126–133
Groh CA, Sharma S, Pelchovitz DJ, Bhave PD, Rhyner J, Verma N, Arora R, Chicos AB, Kim SS, Lin AC, Passman RS, Knight BP (2014) Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm Off J Heart Rhythm Soc 11:1361–1366
Olde Nordkamp LR, Warnaars JL, Kooiman KM, de Groot JR, Rosenmoller BR, Wilde AA, Knops RE (2014) Which patients are not suitable for a subcutaneous icd: incidence and predictors of failed qrs-t-wave morphology screening. J Cardiovasc Electrophysiol 25:494–499
Frommeyer G, Dechering DG, Zumhagen S, Kobe J, Eckardt L, Reinke F (2015) Limitations in s-icd therapy: reasons for system explantation. Clin Res Cardiol. doi:10.1007/s00392-015-0880-x
Sakamoto N, Sato N, Oikawa K, Karim Talib A, Sugiyama E, Minoshima A, Tanabe Y, Takeuchi T, Akasaka K, Saijo Y, Kawamura Y, Hasebe N (2015) Late gadolinium enhancement of cardiac magnetic resonance imaging indicates abnormalities of time-domain t-wave alternans in hypertrophic cardiomyopathy with ventricular tachycardia. Heart Rhythm 12:1747–1755
Flett AS, Maestrini V, Milliken D, Fontana M, Treibel TA, Harb R, Sado DM, Quarta G, Herrey A, Sneddon J, Elliott P, McKenna W, Moon JC (2015) Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. Int J Cardiol 183:143–148
Verrier RL, Nieminen T (2010) T-wave alternans as a therapeutic marker for antiarrhythmic agents. J Cardiovasc Pharmacol 55:544–554
Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV (2014) Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 7:164–170
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W, Investigators M-RT (2012) Reduction in inappropriate therapy and mortality through icd programming. N Engl J Med 367:2275–2283
Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A (2013) Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the advance iii randomized clinical trial. JAMA 309:1903–1911
Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA, de Groot JR (2014) Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to t-wave oversensing can be prevented: implications for management. Heart Rhythm Off J Heart Rhythm Soc 11:426–434
Bellardine Black CL, Stromberg K, van Balen GP, Ghanem RN, Breedveld RW, Tieleman RG (2010) Is surface ecg a useful surrogate for subcutaneous ecg? Pacing Clin Electrophysiol PACE 33:135–145
Brisben AJ, Burke MC, Knight BP, Hahn SJ, Herrmann KL, Allavatam V, Mahajan D, Sanghera R, Gold MR (2015) A new algorithm to reduce inappropriate therapy in the s-icd system. J Cardiovasc Electrophysiol 26:417–423
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
G.F., D.G.D., S.Z., J.K., L.E., and F.R. received travel grants and lecture honoraria from BIOTRONIK, Boston Scientific, Medtronic, Sorin Group and St. Jude Medical.
Rights and permissions
About this article
Cite this article
Frommeyer, G., Dechering, D.G., Zumhagen, S. et al. Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol 105, 89–93 (2016). https://doi.org/10.1007/s00392-015-0901-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-015-0901-9